From Yahoo Finance: 2025-06-11 11:30:00

Merck & Co., Inc. received FDA authorization for a preventative antibody shot to protect infants up to one year old from respiratory syncytial virus (RSV), a common respiratory virus that can lead to pneumonia and death. The antibody, clesrovimab, will be sold under the name Enflonsia and can be taken as a single dose. Merck projects shipments to be ready for the 2025-2026 RSV season, pending CDC recommendations. The company is a global healthcare provider that develops treatments for various conditions and provides vaccines for humans and animals. No promotional content included.



Read more at Yahoo Finance: Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA